Scroll To Top
Search by Speciality

50th American Society of Clinical Oncology (ASCO) Annual Meeting 2014

McCormick Place Convention Center * | Chicago, USA
From 75 to 970 USD
Event Preview
This event
is Finished
Title: 50th American Society of Clinical Oncology (ASCO) Annual Meeting 2014
Specialty: , Radiation Oncology
Dates: From May, 30, 2014 to Jun, 3, 2014
Location: Chicago, USA
Type: Meeting
Registration Cost: From 75 to 970 USD
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Chicago, Usa.
General Info
Event Venue:

McCormick Place Convention Center *

Chicago, USA Visit the Venue to read more
Event Overview
Welcome message:

The 50th American Society of Clinical Oncology (ASCO) Annual Meeting 2014 will be held in Chicago, IL, United States on May 30 - Jun 3, 2014.

The annual meeting of the American Society of Clinical Oncology (ASCO) is dedicated to clinical, molecular and research developments in treatment of cancer.

Biostatistics Breast Cancer - HER2/ER
Joseph P. Costantino, DrPH, Track Leader Shanu Modi, MD, Track Leader
Paul J. Catalano, ScD Tufia C. Haddad, MD
Urania Dafni, ScD Cornelia Liedtke, MD
Susan Halabi, PhD Patrick Glyn Morris
Susan G. Hilsenbeck, PhD Priya Rastogi, MD
Wendy B. London, PhD Alexandra Thomas, MD
Sumithra J. Mandrekar, PhD  
Katherine Panageas, PhD Cancer Prevention/Epidemiology
  Allison W. Kurian, MD, MSc, Track Leader
Breast Cancer - Triple Negative Breast Cancer/Cytotoxics/Loc Susan M. Domchek, MD
Deborah Toppmeyer, MD, Track Leader Samir Khleif, MD
Eleanor Elizabeth Harris, MD Adam J. Olszewski
Steven J. Isakoff, MD, PhD  
Tari A. King, MD  
Joseph A. Sparano, MD Central Nervous System Tumors
Tiffany A. Traina, MD Howard Alan Fine, MD, Track Leader
Janice Maria Walshe, MD Eric L. Chang, MD
  Andrew B. Lassman, MD
Developmental Therapeutics - Clinical Pharmacology & Experimental Christina Tsien, MD
Shivaani Kummar, MD, Track Leader  
Jose Baselga, MD, PhD Developmental Therapeutics - Immunotherapy
Emiliano Calvo John Timmerman, MD, Track Leader
Luis A. Diaz, MD Stephen Maxted Ansell, MD, PhD
Gerald Steven Falchook, MD Charlotte Eielson Ariyan, MD, PhD
Andres Forero-Torres, MD Renier J. Brentjens, MD, PhD
Thehang H. Luu, MD Jonathan S. Cebon, MD, PhD
David C. Smith, MD David S. Hong, MD
Miguel Angel Villalona-Calero, MD Padmanee Sharma, MD, PhD
Timothy Anthony Yap, MBBS, PhD, MRCP, BSc  
  Gastrointestinal (Noncolorectal) Cancer
Gastrointestinal (Colorectal) Cancer Barbara Burtness, MD, Track Leader
George A. Fisher, MD, PhD, Track Leader Waddah B. Al-Refaie, MD
Nancy N. Baxter, MD Karyn A. Goodman, MD 
Emily K. Bergsland, MD Syma Iqbal, MD
Edward Chu, MD Milind M. Javle, MD
Steven J. Cohen, MD Lisa A. Kachnic, MD
Gunnar Folprecht, MD Andrew H. Ko, MD
Georgios Lypas, MD Geoffrey Yuyat Ku, MDMBA
Tony R. Reid, MD, PhD Emil Lou, MD, PhD
Neil Howard Segal, MD, PhD Nipun B. Merchant, MD
Weijing Sun, MD James Posey, MD
Richard H. Wilson  
  Gynecologic Cancer
Genitourinary Cancer Paul Haluska, MD, PhD, Track Leader
Cora N. Sternberg, MD, Track Leader Jonathan S. Berek, MD
Peter Albers, MD Levi S. Downs Jr., MD
Kathleen A. Cooney, MD Rebecca Sophie Kristeleit, MD, PhD
Robert Dreicer, MD Kunle Odunsi, MD
Lauren Christine Harshman, MD David R. Spriggs, MD
Badrinath R. Konety, MD  
Michael J. Morris, MD Health Services Research
Sumanta Kumar Pal, MD Monika K. Krzyzanowska, MD,MPH,FRCPC 
Mark N. Stein, MD Winson Y. Cheung, MD
Scott T. Tagawa, MD Alok A. Khorana, MD
Neha Vapiwala, MD Gary H. Lyman, MDMPHFRCP
  Arden M. Morris, MD
Head and Neck Cancer Helen M. Parsons, PhD
Robert L. Ferris, MD, PhD, FACS, Track Leader Graig Evan Pollack, MD
Jay Boyle, MD  
A. Dimitios Colevas, MD Lung Cancer - Non-small Cell Local-regional/Small Cell/Other
John F. Deeken, MD Scott N. Gettinger, MD, Track Leader
Quynh-Thu Le, MD Julie R. Brahmer, MD
Vassiliki Papadimitrakopoulou, MD Chuong D. Hoang, MD
  Tom John, PhD, FRACPMBBS
Leukemia, Myelodysplasia, and Transplantation Steven M. Keller, MD
Bruno C. Medeiros, MD, Track Leader Gregory J. Riely, MD, PhD
Ravi Bhatia, MD Ralph R. Weichselbaum, MD
Michael Russell Bishop, MDFACP  
Joseph G. Jurcic, MD Lymphoma and Plasma Cell Disorders
Celalettin Ustun, MD Arash A. Alizadeh, MD, PhD, Track Leader
  Alexander M. Lesokhin, MD
Lung Cancer - Non-small Cell Metastatic Saga Lonial, MD
Mark G. Kris, MD, Track Leader Owen A. O’Connor, MD, PhD
Grace K. Dy, MD Saad Zafar Usmani, MDFACP
Leora Horn, MD Michael E. Williams, MD
Joel W. Neal, MD, PhD  
Luis Paz-Ares Melanoma/Skin Cancers
Nathan, A. Pennell, MD, PhD Paul B. Chapman, MD, Track Leader
Lecia V. Sequist, MDMPH Kevin Kim, MD
Howard Jack West, MD Svetomir Markovic, MD, PhD
  Jeffrey Alan Sosman, MD
Patient and Survivor Care  
Tara O. Henderson, MDMPH, Track Leader Pediatric Oncology
Tessa Cigler, MDMPH Jeffrey Toretsky, MD, Track Leader
Shari Beth Goldfarb, MD Lisa Diller, MD
Arif Kamal, MD Stephen Hunger, MD
Monica Alexandra Iriso, MD Clare Twist, MD
Stuart M. Lichtman, MD  
David Spiegel, MD Tumor Biology
  Mark M. Moasser, MD, Track Leader
Sarcoma Michael J. Birrer, MD, PhD
Dennis A. Priebat, MD, Track Leader Sarat Chandarlapaty, MD, PhD
Venkata Ramesh Bulusu, MDFRCR James M. Ford, MD
David R. D’Adamo, MD, PhD David Potter, MD, PhD
Kristen N. Ganjoo, MD Victoria Louise Seewaldt, MD
Registration Not yet available Register Now

Jump to: Group Hotel Reservations

Group Registration

Group registration will open in February 2014.

 The Benefits of Registering as a Group
Group Registration
Individual Registration
Group leaders can be invoiced for the entire group.                                                                
Individuals must pay individually and registrations without payment are not accepted. Registration confirmations serve as an invoice for Individual Attendees.
Communications regarding a group are sent to the group leaders. Communications regarding an individual registrant are sent to that registrant.
Group leaders will need to enter a unique email address to register each Delegate. Individual Attendees must use their login and password to register as a member or guest.
Group leaders are able to arrange badge and meeting materials pick up for the entire group. Individual Attendees receive mailed badges in advance and must pick up meeting materials onsite individually. If badges are not received in advance, the badge may be issued only to the Individual Attendee onsite. Photo identification is required.
Group leaders manage changes to the Delegates in their group. Once an Individual Attendee is registered, only the registrant will have access to the registration for changes and cancellations.
Group Hotel Reservations
  • All group room blocks must be secured directly through the ASCO Annual Meeting Customer Service Center. Please email the following information to secure a room block:

                                   - Name of group and company name representing group.

                                   - Number of rooms required on peak night of conference.

                                   - Complete contact information.

  • Groups will be required to manage their room block reservations through an online room block management website. Information on accessing the website will be sent in early February 2014.
  • Confirmation of the room block will be sent to the Group Leader, along with an invoice for the entire cost of the rooms in the block.
  • An invoice for 100% of the room and tax will be submitted to the group leader and must be paid in full by the payment due date listed on the invoice.
  • All payments for group room blocks are non-refundable.
  • If a group chooses not to use the official Customer Service Center to secure hotel rooms, an additional charge of $300 will be applied to each registrant. These fees must be paid in full before the group’s registration can be processed or registration materials can be released to either the group contact or the individual attendees.
Scientific Content Up to Date
Submission Info

The American Society of Clinical Oncology is now accepting abstracts for presentation and publication at the 2014 Annual Meeting.

With over 30,000 attendees, the ASCO Annual Meeting is one of the largest educational and scientific events in the oncology community—an ideal venue for physicians and scientists to present research results to a global audience of oncology professionals.

Please use the following guidelines to ensure that your abstract information is entered correctly:

Editorial Guidelines for Presented Content:
  • Describe the objectives and results of the research in the abstract so that the ASCO Scientific Program Committee can evaluate the quality, originality, and completeness of the abstract. Abstracts will be judged solely on the basis of the data in the submitted abstract. Statements such as “further data will be available” are discouraged.
  • Organize the abstract according to four sections, identified by the following headers: Background, Methods, Results, and Conclusions. (Note: Trials in Progress abstract submissions should only include Background and Methods sections. Any preliminary data including toxicity, response rate, pharmacokinetic, or correlative analysis should not be included in the abstract.)
  • ASCO does not accept case reports for abstract submission.
  • Adhere to the biostatistical guidelines set forth by the Biostatistics Core of the Scientific Program Committee. Although all of the elements are not required, the absence of one or more of these elements in an abstract may have a negative impact on the abstract review and placement process.
  • Using the box on the Abstract Submitter, indicate whether patients are still being accrued to the study being reported. As a general rule, ASCO discourages submission of abstracts that report interim data from studies that are continuing to accrue patients (examples include phase I studies where recommended phase II dose is not yet determined, or phase II studies that are not fully enrolled). Acceptance of such abstracts will be considered on a case-by-case basis. 
  • Do not refer to study results or conclusions in the title of the abstract. The title should objectively describe the study. ASCO reserves the right to edit conclusive titles. 
  • Do not use proprietary names alone in the title or body of the abstract. If necessary, you may include a proprietary name in parentheses directly after the generic name on first use in the body of the abstract. ASCO reserves the right to replace proprietary names with generic names. 
  • Do not include illustrations with the abstract. You may include one data table created using the Abstract Submitter. 
  • Do not exceed 2,000 characters (approximately 300 to 350 words) for the total of your abstract title, body, and table. The character count does not include spaces or author names or institutions.
  • List no more than 20 individual authors for each abstract. In addition to the 20 authors, an authoring group may also be used. Make sure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors in the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." 
  • Include all coauthors and disclosure information for each coauthor by the February 4deadline. Coauthor disclosure forms are available here.
  • Identify the corresponding author. If you would like someone other than the first author to be contacted with any questions by the ASCO scientific review committee, please designate within the Abstract Submitter. All other correspondence will be with the first author.
  • Although clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication. If a clinical trial is already registered, the first author will be asked to provide the name of the registry and the trial registration number during the abstract submission process. The clinical trial number will be included in the published abstract.
Sponsors Exhibitors
Organising Agency

Use the form below to send an email to ASCO Staff. To contact ASCO by phone, call 571-483-1300 to be directed to the appropriate department. You can also browse our list of additional contacts.

Official Event Webpage
Event map
Revelant Events